Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars M Rasmussen

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
Leukemia & Lymphoma|August 7, 2013
Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone diseaseIda B Kristensen, Jacob Haaber Christensen, Maria B Lyng, et al.
Diabetes Care|October 19, 2013
Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetesVibe Skov, Claudia Cangemi, Jeppe Gram, et al.
Mechanisms of Development|January 11, 2015
Fibulin-1 suppresses endothelial to mesenchymal transition in the proximal outflow tractKeerthi Harikrishnan, Marion A Cooley, Yukiko Sugi, et al.
British Journal of Haematology|February 26, 2013
Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone diseaseIda B Kristensen, Jacob H Christensen, Maria B Lyng, et al.
Diabetes & Vascular Disease Research|August 7, 2014
Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patientsDana Bar-Shalom, Mikael K Poulsen, Lars M Rasmussen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 24, 2012
Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis DPeter Marckmann, Hanne Agerskov, Sasikala Thineshkumar, et al.
Thrombosis Research|March 28, 2013
An ELISA for the quantitation of von Willebrand factor: osteoprotegerin complexes in plasmaPernille J Vinholt, Martin Overgaard, Axel C P Diederichsen, et al.
Plos One|July 12, 2014
Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study)Ruan Kruger, Lars M Rasmussen, William S Argraves, et al.
European Journal of Haematology|April 24, 2013
Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migrationIda B Kristensen, Lise Pedersen, Torstein B Rø, et al.
Annals of Medicine|April 10, 2015
Plasma cytokine levels and risks of abdominal aortic aneurysms: A population-based prospective cohort studyMengyang Liao, Cong-Lin Liu, Bing-Jie Lv, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|August 7, 2013
Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone diseaseIda B Kristensen, Jacob Haaber Christensen, Maria B Lyng, et al.
Diabetes Care|October 19, 2013
Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetesVibe Skov, Claudia Cangemi, Jeppe Gram, et al.
Mechanisms of Development|January 11, 2015
Fibulin-1 suppresses endothelial to mesenchymal transition in the proximal outflow tractKeerthi Harikrishnan, Marion A Cooley, Yukiko Sugi, et al.
British Journal of Haematology|February 26, 2013
Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone diseaseIda B Kristensen, Jacob H Christensen, Maria B Lyng, et al.
Diabetes & Vascular Disease Research|August 7, 2014
Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patientsDana Bar-Shalom, Mikael K Poulsen, Lars M Rasmussen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 24, 2012
Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis DPeter Marckmann, Hanne Agerskov, Sasikala Thineshkumar, et al.
Thrombosis Research|March 28, 2013
An ELISA for the quantitation of von Willebrand factor: osteoprotegerin complexes in plasmaPernille J Vinholt, Martin Overgaard, Axel C P Diederichsen, et al.
Plos One|July 12, 2014
Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study)Ruan Kruger, Lars M Rasmussen, William S Argraves, et al.
European Journal of Haematology|April 24, 2013
Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migrationIda B Kristensen, Lise Pedersen, Torstein B Rø, et al.
Annals of Medicine|April 10, 2015
Plasma cytokine levels and risks of abdominal aortic aneurysms: A population-based prospective cohort studyMengyang Liao, Cong-Lin Liu, Bing-Jie Lv, et al.
Pageof 9